Phase II study of carboplatin in blast crisis of chronic myeloid leukemia: Eastern cooperative oncology group study E1992

J. P. Dutcher, S. Lee, Elisabeth M. Paietta, J. M. Bennett, J. A. Stewart, P. H. Wiernik

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

This study was a phase II evaluation of the activity of carboplatin in patients with Philadelphia chromosome positive accelerated or blastic phase of CML. Carboplatin, 250 mg/m2/day as an intravenous continuous infusion was given for 5 days, for a total dose of 1250 mg/m2 per course. If necessary, a second induction course could be given, and patients achieving complete remission were to receive an additional consolidation cycle at the same dose. Thirty-six patients were eligible and evaluable. There were five complete and three partial remissions for an overall response rate of 22% (95% CI 10.1-39.1%). The complete remission rate was 13.9% (95% CI 4.7-29.9%). The median remission duration was 3 months (range 1.4-8.94 months) and the median survival on study for all patients was 3.5 months (95% CI, 2.4-11.4 months). The median survival of responders was 12.8 months (95% CI, 3.6-17.2 months). Three eligible patients survived 2.0, 2.5 and 3.5 years following carboplatin therapy. Carboplatin has activity in blast crisis of CML, but responses are brief. Response did allow one patient to proceed to bone marrow transplantation and two other patients to continue therapy for chronic phase disease before returning to blast crisis. Activity in combination regimens should be explored.

Original languageEnglish (US)
Pages (from-to)1037-1040
Number of pages4
JournalLeukemia
Volume12
Issue number7
StatePublished - 1998

Fingerprint

Blast Crisis
Carboplatin
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Philadelphia Chromosome
Survival
Bone Marrow Transplantation
Intravenous Infusions
Chronic Disease
Therapeutics

Keywords

  • Blast crisis
  • Carboplatin
  • Chronic myeloid leukemia

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Dutcher, J. P., Lee, S., Paietta, E. M., Bennett, J. M., Stewart, J. A., & Wiernik, P. H. (1998). Phase II study of carboplatin in blast crisis of chronic myeloid leukemia: Eastern cooperative oncology group study E1992. Leukemia, 12(7), 1037-1040.

Phase II study of carboplatin in blast crisis of chronic myeloid leukemia : Eastern cooperative oncology group study E1992. / Dutcher, J. P.; Lee, S.; Paietta, Elisabeth M.; Bennett, J. M.; Stewart, J. A.; Wiernik, P. H.

In: Leukemia, Vol. 12, No. 7, 1998, p. 1037-1040.

Research output: Contribution to journalArticle

Dutcher, JP, Lee, S, Paietta, EM, Bennett, JM, Stewart, JA & Wiernik, PH 1998, 'Phase II study of carboplatin in blast crisis of chronic myeloid leukemia: Eastern cooperative oncology group study E1992', Leukemia, vol. 12, no. 7, pp. 1037-1040.
Dutcher, J. P. ; Lee, S. ; Paietta, Elisabeth M. ; Bennett, J. M. ; Stewart, J. A. ; Wiernik, P. H. / Phase II study of carboplatin in blast crisis of chronic myeloid leukemia : Eastern cooperative oncology group study E1992. In: Leukemia. 1998 ; Vol. 12, No. 7. pp. 1037-1040.
@article{7e03cdc0e45042aeb7a32bb1a8b7b392,
title = "Phase II study of carboplatin in blast crisis of chronic myeloid leukemia: Eastern cooperative oncology group study E1992",
abstract = "This study was a phase II evaluation of the activity of carboplatin in patients with Philadelphia chromosome positive accelerated or blastic phase of CML. Carboplatin, 250 mg/m2/day as an intravenous continuous infusion was given for 5 days, for a total dose of 1250 mg/m2 per course. If necessary, a second induction course could be given, and patients achieving complete remission were to receive an additional consolidation cycle at the same dose. Thirty-six patients were eligible and evaluable. There were five complete and three partial remissions for an overall response rate of 22{\%} (95{\%} CI 10.1-39.1{\%}). The complete remission rate was 13.9{\%} (95{\%} CI 4.7-29.9{\%}). The median remission duration was 3 months (range 1.4-8.94 months) and the median survival on study for all patients was 3.5 months (95{\%} CI, 2.4-11.4 months). The median survival of responders was 12.8 months (95{\%} CI, 3.6-17.2 months). Three eligible patients survived 2.0, 2.5 and 3.5 years following carboplatin therapy. Carboplatin has activity in blast crisis of CML, but responses are brief. Response did allow one patient to proceed to bone marrow transplantation and two other patients to continue therapy for chronic phase disease before returning to blast crisis. Activity in combination regimens should be explored.",
keywords = "Blast crisis, Carboplatin, Chronic myeloid leukemia",
author = "Dutcher, {J. P.} and S. Lee and Paietta, {Elisabeth M.} and Bennett, {J. M.} and Stewart, {J. A.} and Wiernik, {P. H.}",
year = "1998",
language = "English (US)",
volume = "12",
pages = "1037--1040",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Phase II study of carboplatin in blast crisis of chronic myeloid leukemia

T2 - Eastern cooperative oncology group study E1992

AU - Dutcher, J. P.

AU - Lee, S.

AU - Paietta, Elisabeth M.

AU - Bennett, J. M.

AU - Stewart, J. A.

AU - Wiernik, P. H.

PY - 1998

Y1 - 1998

N2 - This study was a phase II evaluation of the activity of carboplatin in patients with Philadelphia chromosome positive accelerated or blastic phase of CML. Carboplatin, 250 mg/m2/day as an intravenous continuous infusion was given for 5 days, for a total dose of 1250 mg/m2 per course. If necessary, a second induction course could be given, and patients achieving complete remission were to receive an additional consolidation cycle at the same dose. Thirty-six patients were eligible and evaluable. There were five complete and three partial remissions for an overall response rate of 22% (95% CI 10.1-39.1%). The complete remission rate was 13.9% (95% CI 4.7-29.9%). The median remission duration was 3 months (range 1.4-8.94 months) and the median survival on study for all patients was 3.5 months (95% CI, 2.4-11.4 months). The median survival of responders was 12.8 months (95% CI, 3.6-17.2 months). Three eligible patients survived 2.0, 2.5 and 3.5 years following carboplatin therapy. Carboplatin has activity in blast crisis of CML, but responses are brief. Response did allow one patient to proceed to bone marrow transplantation and two other patients to continue therapy for chronic phase disease before returning to blast crisis. Activity in combination regimens should be explored.

AB - This study was a phase II evaluation of the activity of carboplatin in patients with Philadelphia chromosome positive accelerated or blastic phase of CML. Carboplatin, 250 mg/m2/day as an intravenous continuous infusion was given for 5 days, for a total dose of 1250 mg/m2 per course. If necessary, a second induction course could be given, and patients achieving complete remission were to receive an additional consolidation cycle at the same dose. Thirty-six patients were eligible and evaluable. There were five complete and three partial remissions for an overall response rate of 22% (95% CI 10.1-39.1%). The complete remission rate was 13.9% (95% CI 4.7-29.9%). The median remission duration was 3 months (range 1.4-8.94 months) and the median survival on study for all patients was 3.5 months (95% CI, 2.4-11.4 months). The median survival of responders was 12.8 months (95% CI, 3.6-17.2 months). Three eligible patients survived 2.0, 2.5 and 3.5 years following carboplatin therapy. Carboplatin has activity in blast crisis of CML, but responses are brief. Response did allow one patient to proceed to bone marrow transplantation and two other patients to continue therapy for chronic phase disease before returning to blast crisis. Activity in combination regimens should be explored.

KW - Blast crisis

KW - Carboplatin

KW - Chronic myeloid leukemia

UR - http://www.scopus.com/inward/record.url?scp=0031875109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031875109&partnerID=8YFLogxK

M3 - Article

C2 - 9665187

AN - SCOPUS:0031875109

VL - 12

SP - 1037

EP - 1040

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 7

ER -